Skip to main content

ANEB

Stock
Health Care
Biotechnology

Performance overview

ANEB Price
Price Chart

Forward-looking statistics

Beta
0.41
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Company info

SectorHealth Care
IndustryBiotechnology
Employees2
Market cap$56.3M

Fundamentals

Enterprise value$45.9M
Revenue$0.0
Revenue per employee—
Profit margin0.00%
Debt to equity0.00

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.25
Dividend per share—
Revenue per share$0.00
Avg trading volume (30 day)$22K
Avg trading volume (10 day)$42K
Put-call ratio—

Macro factor sensitivity

Growth+3.5
Credit-2.7
Liquidity-1.1
Inflation+0.7
Commodities+2.3
Interest Rates+1.5

Valuation

Dividend yield0.00%
PEG Ratio-2.58
Price to sales—
P/E Ratio-2.58
Enterprise Value to Revenue—
Price to book5.12

Upcoming events

Next earnings daySeptember 23, 2025
Next dividend day—
Ex. dividend day—

News

Are Medical Stocks Lagging Anebulo Pharmaceuticals (ANEB) This Year?

Here is how Anebulo Pharmaceuticals, Inc. (ANEB) and Conmed (CNMD) have performed compared to their sector so far this year.

Zacks Investment Research (October 19, 2023)
Anebulo's ANEB-001 Reduces Cannabis Intoxication In Healthy Participants

Anebulo Pharmaceuticals IncĀ (NASDAQ: ANEB)Ā has announcedĀ topline data from Part A of an ongoing Phase 2 trial of ANEB-001 to treat acute cannabinoid intoxication (ACI).Ā  Part A was a 60-subject trial designed to evaluate the effectiveness of a single dose of ANEB-001 in healthy.

Benzinga (July 5, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free